Drug Trial Radar · NCT07202949
A Clinical Trial of Extended (High) Treatment Dose Antibiotics in Combination With Methenamine Hippurate Compared to the Standard of Care (Either Prophylactic (Low) Dose Antibiotic Treatment or Methenamine Hippurate) in Females With Chronic Urinary Tract Infection
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
192
Planned (sponsor's estimate)
Start
Feb 26, 2026
Primary completion
Oct 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- University College, LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Chronic Urinary Tract Infection (UTI) is a type of UTI where symptoms are constant and occur every day, unlike recurrent UTIs, which come and go with symptom-free breaks in between. Current treatment for chronic UTI within the NHS is based on recommended guidelines for recurrent UTI. The standard approach typically includes one of the following treatments: * Long-term, prophylactic (low) dose daily antibiotic (where medication is used at low doses to try to prevent symptoms reoccurring). * Long-term use of a urinary antiseptic (which helps keep your urine bacteria free), called methenamine hippurate. These often do not work for people with chronic UTI, and symptoms can persist. Moreover, standard urine tests may fail to detect infections, making diagnosis and treatment more challenging. The EAT-UP trial will investigate whether longer courses of treatment (higher) dose antibiotics combined with methenamine hippurate (a urinary antiseptic) are a more effective treatment at reducing levels of infection and symptoms than standard of care treatments (as described above).
Conditions
- Chronic Urinary Tract Infection
Interventions
Treatment dose antibiotic in combination with methenamine hippurateDrug
Arm A includes treatment with one of three treatment dose antibiotic options, selected by the treating clinician, in combination with methenamine hippurate. Participants allocated to this arm will receive combination therapy, consisting of one of the following antibiotics: * Cefalexin (500mg four times daily), or * Nitrofurantoin (100mg twice daily), or * Trimethoprim (200mg twice daily) in combination with Methenamine Hippurate (1g twice daily) for 12 weeks.
Prophylactic dose antibiotic or methenamine hippurate monotherapyDrug
Arm B includes treatment with one of four prophylactic dose antibiotics or methenamine hippurate, but not both, selected by the treating clinician. Participants in this arm will receive monotherapy of one of the following: * Amoxicillin (250mg once daily), or * Cefalexin (125mg once daily), or * Nitrofurantoin (50mg once daily), or * Trimethoprim (100mg once daily), or * Methenamine Hippurate (1g twice daily) for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in urinary white blood cell (WBC) count from baseline to Week 12.Time frame: Baseline, Week 4, Week 8, Week 12
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
University College London Hospital (UCLH), UCLH NHS Foundation Trust
London, United Kingdom · Recruiting
Whittington Hospital, Whittington Health NHS Trust
London, United Kingdom · Recruiting
St Mary's Hospital, Manchester University NHS Foundation Trust
Manchester, United Kingdom · Recruiting
Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom · Recruiting
Scunthorpe General Hospital and Diana, Princess of Wales Hospital ; Northern Lincolnshire and Goole NHS Foundation Trust
Yorkshire, Humber, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.